scholarly journals A Single-Blinded Randomized Controlled Trial of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee with Active Control

2021 ◽  
Vol 17 (1) ◽  
Keyword(s):  
Randomized Controlled Trial ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Active Control ◽  
Stem Cell Therapy ◽  
Controlled Trial ◽  
Osteoarthritis Of The Knee ◽  
Mesenchymal Stem Cell Therapy ◽  
Randomized Controlled

Should Mesenchymal Stem Cell Therapy be used in the treatment of COVID-19?

2020 ◽  
Vol 54 ◽  
Author(s):  
Namnama P. Villarta-De Dios ◽  
Evelyn S. Osio-Salido
Keyword(s):  
Stem Cells ◽  
Randomized Controlled Trial ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Standard Treatment ◽  
Controlled Trial ◽  
Mesenchymal Stem Cell Therapy ◽  
Randomized Controlled

KEY FINDINGSThere is some short-term benefit from the use of mesenchymal stem cell therapy for severe COVID-19 in a lowquality, small randomized controlled trial (RCT). Further studies, ideally with good quality RCTs, are needed toconfirm benefit and safety.• Mesenchymal stem cells (MSCs) are non-hematopoietic adult stem cells that are able to self-renew anddifferentiate into various cells of any cell lineage. MSCs have the ability to migrate (homing) to damaged tissuefor repair and regeneration, as well as signal other cells to help in tissue repair. It can effect cellular differentiation,consequently shifting the immune system from Th1 to Th2 responses.1,2• A recent review showed improved disease-associated parameters in experimental acute respiratory distresssyndrome (ARDS).3• We found three studies (one case report, one prospective cohort, and one small randomized controlled trial)reporting the effects of MSC on COVID-19. Based on low-quality evidence, it appeared that human umbilicalcord blood-derived MSC, given after failure to improve with standard treatment, had beneficial effects in termsof earlier onset of clinical improvement among individuals with severe or critical COVID-19. However, 28-dayclinical improvement and mortality were not significantly different compared to standard treatment. There wasno reported adverse reaction.• There are 52 registered and ongoing clinical trials to investigate the efficacy and safety of mesenchymal stemcells as treatment for COVID-19.• Mesenchymal stem cell therapy is not included in any of the existing guidelines for the treatment of COVID-19.

scholarly journals Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study

2020 ◽  
Vol 11 ◽  
Author(s):  
Jan Horak ◽  
Lukas Nalos ◽  
Vendula Martinkova ◽  
Vaclav Tegl ◽  
Lucie Vistejnova ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Mesenchymal Stem Cell Therapy ◽  
Randomized Controlled

Steroids reduce the efficacy of mesenchymal stem cell therapy for liver cirrhosis

Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S48-S50 ◽  
Author(s):  
Xiaodong Chen ◽  
Yurun Gan ◽  
Ying Wang ◽  
Yufang Shi
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Mesenchymal Stem Cell Therapy
Sign in / Sign up

Export Citation Format

Share Document